Dana-Farber Phase 2 Trial Demonstrates Durable and Profound Responses to CAR T-Cell Therapy in High-Risk Smoldering Multiple Myeloma
In a groundbreaking advancement for blood cancer therapies, Dana-Farber Cancer Institute has presented compelling results from the phase 2 CAR-PRISM ...
